Real-world study of treatments for MET-mutation lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how different treatments work for people with advanced lung cancer that has a MET mutation. It aims to understand real-world treatment patterns and outcomes to help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced non-small cell lung cancer that cannot be removed with surgery (stage IIIB/IIIC or IV)
- Your tumor has a MET mutation, confirmed by a genetic test called NGS
- You are willing and able to give permission to participate in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This trial tests REGN5093, a study drug, in adults with advanced lung cancer that has a specific change called a MET alteration. If you have this MET change, the study aims to see how well the drug controls the cancer and how safe it is.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
This study looks at real-world treatment for non-small cell lung cancer with a specific genetic change (EGFR mutation). It might help researchers understand how different treatments work in daily practice.
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.